Organon & Co.
HealthcareNYSE:OGN · New York Stock Exchange
-$0.01 today
Vol 1.81M · Avg 8.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
24.9%
avg -147.4%
ROIC
5.4%
avg 18.2%
ROA
1.5%
avg 12.2%
Analysis
ROE is currently the strongest return metric at 24.9% versus its period average of -147.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Matthew Walsh | Executive Vice President & Chief Financial Officer | $1.69M | — | 59 | $321,368.00 | 0.12% |
Joseph T. Morrissey Jr. | Chief Executive Officer | $1.66M | — | 61 | $333,889.00 | 0.13% |
Juan Camilo Arjona Ferreira | Executive Vice President, Head of Research & Development and Chief Medical Officer | $1.33M | — | 55 | $200,333.00 | 0.08% |
Rachel A. Stahler | Executive VP, Chief Information Officer and Chief Digital & Growth Officer | $1.27M | — | 50 | $183,639.00 | 0.07% |
Kirke Weaver | Executive Vice President, General Counsel & Corporate Secretary | $1.26M | — | 53 | $183,639.00 | 0.07% |
Carrie Smith Cox | Executive Chair of the Board | $220,645.00 | — | 67 | $77,869.00 | 0.03% |
Juliana Papa Drinane | Interim Head of Manufacturing & Supply | — | — | — | $0.00 | <0.01% |
Daniel Karp | Chief Strategy Officer & Head of Corporate Development | — | — | 48 | $100,166.00 | 0.04% |
Aaron Falcione | Executive Vice President & Chief Human Resources Officer | — | — | 55 | $166,944.00 | 0.06% |
Mike Casia | Interim Head of U.S. Commercial & Government Affairs | — | — | — | — | — |
Nico Van Hoecke | Head of International Commercial | — | — | — | — | — |
Vittorio Nisita | Executive Vice President & Head of Enterprise Services and Solutions | — | — | 58 | $125,208.00 | 0.05% |
Jennifer Halchak | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$854,835.74
Sells
1
$353,080.40
Net Sentiment
+$501,755.34
Net buying
Most Active
Holzbaur Lynette
2 transactions
Analysis
Insiders reported 2 buys worth $854,835.74 and 1 sells worth $353,080.40 over the last 12 months. That adds up to net buying of $501,755.34. Holzbaur Lynette was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -14.4% | -3.4% (9yr)1 analysts |
| Revenue | N/A | N/A | -13.6% | +0.3% (9yr)2 analysts |
| Net Income | N/A | N/A | -14.4% | -3.1% (9yr)2 analysts |
| EBIT | N/A | N/A | -10.9% | -3.4% (9yr)2 analysts |
Analysis
Recent growth has been strongest in EBIT at -10.9% over three years. Forward estimates point to Revenue at +0.3% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.73B
Avadel Pharmaceuticals plc
AVDL
$2.12B
Select Medical Holdings Corporation
NYSE:SEM
$2.07B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.03B
Pediatrix Medical Group, Inc.
NYSE:MD
$2.00B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Alvotech
NASDAQ:ALVO
$1.30B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
Who manages OGN?
Organon & Co. (OGN) lists 13 active executives. The top listed executive is Kirke Weaver, Executive Vice President, General Counsel & Corporate Secretary.
Are OGN insiders buying or selling?
Recent insider activity shows net buying of $6.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.